At the conclusion of this activity, participants will be able to:

1. Describe the clinical characteristics, presentation, and diagnosis of struma ovarii

2. Be familiar with standard approach to treatment

3. Understand the role of the multi-kinase inhibitor lenvatinib in refractory disease 


Session date: 
02/14/2019 - 1:00pm to 2:00pm CST
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Lorraine Canham, MD